Osteoporosis Drugs Market Size Worth USD 20.53 Billion in 2032 | Emergen Research
18 janv. 2024 10h15 HE
|
Emergen Research
Vancouver, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The global osteoporosis drugs market size was USD 13.06 billion in 2022 and is expected to register a revenue CAGR of 4.7% during the forecast period....
Societal CDMO Reports Inducement Grants for New Staff
05 janv. 2024 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT
13 déc. 2023 07h30 HE
|
Mangoceuticals, Inc.
The Dallas Based, Direct-to-Consumer Telemedicine Company Secures Marketing Agreement with Marius Pharmaceuticals Bringing KYZATREX to the Telehealth Market as ‘Prime’ by MangoRx Dallas, Texas...
ROSEN, NATIONAL TRIAL LAWYERS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYX
18 nov. 2023 15h33 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 18, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Jeremy Caldwell, Ph.D., Accomplished Biopharma Executive, Company Creator and R&D Leader, Joins Red Tree Venture Capital as Partner
16 nov. 2023 07h00 HE
|
Red Tree Venture Capital
Former Venture Partner at Versant Ventures and CEO of Inception, Versant’s San Diego Company Creation Engine, Brings Red Tree Strong Ties to San Diego Biopharmaceutical Ecosystem Addition of Dr....
Proxygen Announces Formation of Scientific Advisory Board
15 nov. 2023 07h00 HE
|
Proxygen
SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine Track Records of Founding Biopharma Companies and...
Societal CDMO Reports Third Quarter 2023 Financial Results
08 nov. 2023 16h05 HE
|
Societal CDMO, Inc.
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated...
Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023
01 nov. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
Societal CDMO Reports Inducement Grants for New Staff
05 oct. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers
07 sept. 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...